Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.790803/full |
| _version_ | 1798026669536051200 |
|---|---|
| author | Szymon Hryhorowicz Marta Kaczmarek-Ryś Aleksandra Zielińska Rodney J. Scott Rodney J. Scott Ryszard Słomski Andrzej Pławski |
| author_facet | Szymon Hryhorowicz Marta Kaczmarek-Ryś Aleksandra Zielińska Rodney J. Scott Rodney J. Scott Ryszard Słomski Andrzej Pławski |
| author_sort | Szymon Hryhorowicz |
| collection | DOAJ |
| description | Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in modulating many physiological processes including intestinal homeostasis, modulation of gastrointestinal motility, visceral sensation, or immunomodulation of inflammation in IBD. It consists of cannabinoid receptors (CB1 and CB2), transporters for cellular uptake of endocannabinoid ligands, endogenous bioactive lipids (Anandamide and 2-arachidonoylglycerol), and the enzymes responsible for their synthesis and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), the manipulation of which through agonists and antagonists of the system, shows a potential therapeutic role for ECS in inflammatory bowel disease. This review summarizes the role of ECS components on intestinal inflammation, suggesting the advantages of cannabinoid-based therapies in inflammatory bowel disease. |
| first_indexed | 2024-04-11T18:38:53Z |
| format | Article |
| id | doaj.art-b191c90df5344eee90756ba444aa7fc2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T18:38:53Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b191c90df5344eee90756ba444aa7fc22022-12-22T04:09:04ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-12-011210.3389/fimmu.2021.790803790803Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic ReviewSzymon Hryhorowicz0Marta Kaczmarek-Ryś1Aleksandra Zielińska2Rodney J. Scott3Rodney J. Scott4Ryszard Słomski5Andrzej Pławski6Institute of Human Genetics, Polish Academy of Sciences, Poznań, PolandInstitute of Human Genetics, Polish Academy of Sciences, Poznań, PolandInstitute of Human Genetics, Polish Academy of Sciences, Poznań, PolandDiscipline of Medical Genetics and Centre for Information-Based Medicine, The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, AustraliaDivision of Molecular Medicine, New South Wales Health Pathology North, Newcastle, NSW, AustraliaInstitute of Human Genetics, Polish Academy of Sciences, Poznań, PolandInstitute of Human Genetics, Polish Academy of Sciences, Poznań, PolandInflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in modulating many physiological processes including intestinal homeostasis, modulation of gastrointestinal motility, visceral sensation, or immunomodulation of inflammation in IBD. It consists of cannabinoid receptors (CB1 and CB2), transporters for cellular uptake of endocannabinoid ligands, endogenous bioactive lipids (Anandamide and 2-arachidonoylglycerol), and the enzymes responsible for their synthesis and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), the manipulation of which through agonists and antagonists of the system, shows a potential therapeutic role for ECS in inflammatory bowel disease. This review summarizes the role of ECS components on intestinal inflammation, suggesting the advantages of cannabinoid-based therapies in inflammatory bowel disease.https://www.frontiersin.org/articles/10.3389/fimmu.2021.790803/fullinflammatory bowel diseasethe endocannabinoid systemcannabinoid receptorcannabisulcerative colitisCrohn's disease |
| spellingShingle | Szymon Hryhorowicz Marta Kaczmarek-Ryś Aleksandra Zielińska Rodney J. Scott Rodney J. Scott Ryszard Słomski Andrzej Pławski Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review Frontiers in Immunology inflammatory bowel disease the endocannabinoid system cannabinoid receptor cannabis ulcerative colitis Crohn's disease |
| title | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
| title_full | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
| title_fullStr | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
| title_full_unstemmed | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
| title_short | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
| title_sort | endocannabinoid system as a promising therapeutic target in inflammatory bowel disease a systematic review |
| topic | inflammatory bowel disease the endocannabinoid system cannabinoid receptor cannabis ulcerative colitis Crohn's disease |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.790803/full |
| work_keys_str_mv | AT szymonhryhorowicz endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT martakaczmarekrys endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT aleksandrazielinska endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT rodneyjscott endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT rodneyjscott endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT ryszardsłomski endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT andrzejpławski endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview |